List of Excipients in API rucaparib
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing rucaparib
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Clovis Oncology Inc | RUBRACA | rucaparib | 69660-201 | CELLULOSE, MICROCRYSTALLINE | 2035-08-17 |
| Clovis Oncology Inc | RUBRACA | rucaparib | 69660-201 | FD&C BLUE NO. 1 | 2035-08-17 |
| Clovis Oncology Inc | RUBRACA | rucaparib | 69660-201 | FD&C BLUE NO. 2 | 2035-08-17 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for rucaparib
Excipient focus: CELLULOSE, MICROCRYSTALLINE
rucaparib drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Clovis Oncology Inc | rucaparib | 69660-201 |
| pharmaand GmbH | rucaparib | 82154-0783 |
| >Company | >Ingredient | >NDC |
rucaparib drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FD&C BLUE NO. 1
rucaparib drug variants containing FD&C BLUE NO. 1
| Company | Ingredient | NDC |
|---|---|---|
| Clovis Oncology Inc | rucaparib | 69660-201 |
| pharmaand GmbH | rucaparib | 82154-0783 |
| >Company | >Ingredient | >NDC |
rucaparib drug variants not containing FD&C BLUE NO. 1
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FD&C BLUE NO. 2
rucaparib drug variants containing FD&C BLUE NO. 2
| Company | Ingredient | NDC |
|---|---|---|
| Clovis Oncology Inc | rucaparib | 69660-201 |
| pharmaand GmbH | rucaparib | 82154-0783 |
| >Company | >Ingredient | >NDC |
rucaparib drug variants not containing FD&C BLUE NO. 2
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
rucaparib drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Clovis Oncology Inc | rucaparib | 69660-201 |
| pharmaand GmbH | rucaparib | 82154-0783 |
| >Company | >Ingredient | >NDC |
rucaparib drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL
rucaparib drug variants containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Clovis Oncology Inc | rucaparib | 69660-201 |
| pharmaand GmbH | rucaparib | 82154-0783 |
| >Company | >Ingredient | >NDC |
rucaparib drug variants not containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYVINYL ALCOHOL
rucaparib drug variants containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Clovis Oncology Inc | rucaparib | 69660-201 |
| pharmaand GmbH | rucaparib | 82154-0783 |
| >Company | >Ingredient | >NDC |
rucaparib drug variants not containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
rucaparib drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Clovis Oncology Inc | rucaparib | 69660-201 |
| pharmaand GmbH | rucaparib | 82154-0783 |
| >Company | >Ingredient | >NDC |
rucaparib drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM STARCH GLYCOLATE TYPE A POTATO
rucaparib drug variants containing SODIUM STARCH GLYCOLATE TYPE A POTATO
| Company | Ingredient | NDC |
|---|---|---|
| Clovis Oncology Inc | rucaparib | 69660-201 |
| pharmaand GmbH | rucaparib | 82154-0783 |
| >Company | >Ingredient | >NDC |
rucaparib drug variants not containing SODIUM STARCH GLYCOLATE TYPE A POTATO
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
rucaparib drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| Clovis Oncology Inc | rucaparib | 69660-201 |
| pharmaand GmbH | rucaparib | 82154-0783 |
| >Company | >Ingredient | >NDC |
rucaparib drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
rucaparib drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Clovis Oncology Inc | rucaparib | 69660-201 |
| pharmaand GmbH | rucaparib | 82154-0783 |
| >Company | >Ingredient | >NDC |
rucaparib drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
